ABSTRACT
PURPOSE: To evaluate the therapeutic effect of topical mitomycin C (MMC) on the diffuse conjunctival-corneal intraepithelial neoplasia (CCIN). METHODS: Three patients histopathologically confirmed the conjunctival-corneal intraepithelial neoplasia (CCIN) received topical drop of 0.04% MMC four times daily for 2 to 4 weeks. Ocular complications and recurrence were evaluated under slit lamp biomicroscope. RESULTS: One case received topical drop of 0.04% MMC four times daily for 2 weeks and two cases of CCIN received for 4 weeks in the same manner. These lesions were completely regressed and did not recur under slit lamp biomicroscope during the follow-up of 18 months, 6 months, and 5 months, respectively. Other complications except superficial punctate keratitis and conjunctival injection did not develope and visual acuities have been improved. CONCLUSIONS: It appears that the application of topical MMC alone could be a primary effective treatment for diffuse conjunctival-corneal intraepithelial neoplasia (CCIN).
Subject(s)
Humans , Follow-Up Studies , Keratitis , Mitomycin , Recurrence , Visual AcuityABSTRACT
PURPOSE: To investigate the effect of topical Mitomycin C(MMC) as a medical adjunct to incompletely excised conjunctival-corneal intraepithelial neoplasia(CCIN) for removal of remaining neoplastic cells and prevention of recurrence. METHODS: The authors applied postoperative topical 0.02% MMC adjunctively on 2 eyes of 2 patients with incompletely excised and histopathologically confirmed conjunctival-corneal intraepithelial neoplasia(CCIN) for 2weeks and if the lesion is not regressed, topical MMC treatment with the same regimen was added. RESULTS: Remaining lesions were completely regressed and no recurrence has been found with follow up to 25 months and 26 months in each case. CONCLUSIONS: Topical MMC chemotherapy would be an effective treatment modality on incompletely excised conjunctival-corneal intraepithelial neoplasia(CCIN) for removal of remaining neoplatic cells and prevention of recurrence.